Skip to main content
Clinical Trials/NCT04671641
NCT04671641
Completed
Not Applicable

Prospective, Multi-center, Randomized Controlled Study to Evaluate the Effectiveness and Safety of Endovenous Radiofrequency Ablation Closure System in the Treatment of Varicose Veins

Suzhou Hengruihongyuan Medical Technology Co. LTD5 sites in 1 country176 target enrollmentMarch 24, 2021
ConditionsVaricose Veins

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Varicose Veins
Sponsor
Suzhou Hengruihongyuan Medical Technology Co. LTD
Enrollment
176
Locations
5
Primary Endpoint
Vascular closure rate at 6 months after the operation
Status
Completed
Last Updated
10 months ago

Overview

Brief Summary

The goal of this clinical trial is to evaluate the effectiveness and safety of the endovenous radiofrequency ablation closure system produced by Suzhou Hengrui Hongyuan Medical Technology Co., Ltd. for the treatment of varicose veins.

Detailed Description

In this prospective, multi-center, randomized controlled study, 176 patients who were diagnosed with varicose veins and met the inclusion criteria without any exclusion criteria were randomly divided into the experimental group (Hongyuan Endovenous Radiofrequency Ablation Closure System)and control group (Medtronic's ClosureFast™ Radiofrequency Ablation System) at 1:1. The effectiveness of the product was evaluated by the vascular closure rate at 6 months after the operation, and the safety of the product was evaluated by the incidence of adverse events and serious adverse events within 6 months after the operation.

Registry
clinicaltrials.gov
Start Date
March 24, 2021
End Date
July 1, 2022
Last Updated
10 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Suzhou Hengruihongyuan Medical Technology Co. LTD
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 18-80 years old, no gender limit.
  • Great saphenous varicose, CEAP grade C2-C
  • The diameter of the diseased vein is ≥2mm, ≤15mm.
  • Expected survival period ≥ 6 months.
  • The informed consent form can be signed by the patient or the legal representative.

Exclusion Criteria

  • Are pregnant or breastfeeding.
  • Participating in clinical trials of other devices or drugs.
  • Deep vein thrombosis in the affected limb.
  • Uncorrectable coagulation dysfunction and obvious abnormal blood picture, with obvious bleeding tendency (platelets≤30x109/L).
  • Acute thrombosis in the main saphenous vein of the affected limb.
  • The investigator judged that it is not suitable to participate in the clinical trial.

Outcomes

Primary Outcomes

Vascular closure rate at 6 months after the operation

Time Frame: 6 months

Calculation method: completely closed patients / total cases of subjects in the same group x 100%. Definition of complete closure: Complete closure refers to ultrasound follow-up at 6 months after surgery that shows no blood flow in varicose veins.

Secondary Outcomes

  • Technical success rate(6 months)
  • CEAP(6 months)
  • Evaluation of the use of devices(6 months)
  • VCSS(6 months)

Study Sites (5)

Loading locations...

Similar Trials